This 1999 meta-analysis by Allison et al. systematically reviewed the extent of weight gain associated with various antipsychotic medications. The study found that clozapine and olanzapine were associated with the most significant weight gain, with average increases of 4.45 kg and 4.15 kg, respectively, over a 10-week period. Risperidone and
This 2022 protocol, published in Contemporary Clinical Trials, outlines a planned double-blind, placebo-controlled randomized clinical trial to assess the efficacy of oral naltrexone in treating adolescent eating disorders, specifically anorexia nervosa and bulimia nervosa. The study aims to enroll adolescents aged 12–21 who exhibit binge/purge behaviors, administering 50 mg of
This 1997 randomized, double-blind, placebo-controlled crossover study, published in Physiology & Behavior, investigated the role of endogenous opioids in modulating appetite and food intake. Twenty healthy adult participants received either 50 mg of naltrexone or a placebo before consuming a standardized meal. The study found that naltrexone significantly reduced food
This 2019 case series, published in the Journal of Child and Adolescent Psychopharmacology, examines the effects of low-dose naltrexone (LDN) on adolescents with eating disorders characterized by binge eating and purging behaviors. Conducted at Children’s Mercy Kansas City, the study involved a small cohort of adolescents who received LDN as
This 2010 randomized, double-blind, placebo-controlled crossover trial, published in Annals of Neurology, evaluated the impact of low-dose naltrexone (LDN) on quality of life in patients with multiple sclerosis (MS). Conducted by Cree et al. at the University of California, San Francisco, the study involved 80 participants with relapsing-remitting or secondary
This systematic review, published in Archives of Medical Science in 2021, assessed the safety and efficacy of naltrexone and the naltrexone/bupropion combination for weight loss in adults. The authors analyzed 14 studies, including one meta-analysis, ten randomized controlled trials, and three non-randomized studies, encompassing a total of 191 articles initially
In this 2012 randomized, double-blind, placebo-controlled trial, Afshar et al. evaluated the efficacy of N-acetylcysteine (NAC) as an adjunctive treatment for patients with treatment-refractory obsessive-compulsive disorder (OCD). Forty-eight participants (mean age 30.9 years; 75% female) who had not responded to serotonin reuptake inhibitors (SRIs) were randomized to receive either NAC
This 2021 randomized, double-blind, placebo-controlled pilot study by Grilo et al. evaluated the efficacy and safety of a 16-week treatment with naltrexone/bupropion (NB) in adults with binge-eating disorder (BED) and obesity. Thirty-two participants (mean age 46.6 years; 84% female; mean BMI 37.2 kg/m²) were randomized to receive either NB or
This 2023 randomized, double-blind, placebo-controlled trial by Grilo et al. assessed the efficacy of naltrexone/bupropion (NB) as a maintenance treatment for adults with binge-eating disorder (BED) and comorbid obesity who had responded to acute treatment. Sixty-six participants (84.8% women; mean age 46.9; mean BMI 34.9 kg/m²) who achieved remission following
This 2022 review by Vukojević et al. explores the neuroprotective and neuromodulatory effects of BPC 157, a stable gastric pentadecapeptide, on the central nervous system (CNS). The authors discuss preclinical studies demonstrating BPC 157’s efficacy in various CNS disorders, including traumatic brain injury, stroke, spinal cord injury, and neuropsychiatric conditions.
